Authors

Latest:

Politics & Policy: March 2007

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.

Dianna S. Howard, MD

Latest:

Marking 25 Years of Progress in Blood and Marrow Transplantation

While major accomplishments in blood and marrow transplantation (BMT) were being made around the country, the first BMT program at Wake Forest Baptist came into view, a vision brought to life by David D. Hurd, MD.

Dicken Shiu-Chung Ko, MD

Latest:

Dr. Ko on Renal Transplantation Following Tumor Excision

Dicken Shiu-Chung Ko, MD, Department of Urology, Massachusetts General Hospital, discusses current evidence of renal transplantation following tumor excision.

Diego Villa, MD, MPH

Latest:

Dr. Villa on Rationale for Examining BR as Induction Therapy in Transplant-Eligible MCL

Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.

Dieter Zopf

Latest:

Clinical Development of Regorafenib Combinations in Pediatric Rhabdomyosarcoma

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.

Dietmar Berger, Global Head of Development, Sanofi Sponsored Content by Sanofi

Dimitrios Tzachanis, MD, PhD

Latest:

Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in Lymphoma

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Dimitry Gabrilovitch MD PhD

Latest:

Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue Sarcomas

Neoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.

Dimosthenis Andreou, MD

Latest:

Dr. Dimosthenis on Prognosis Factors in Ewing Sarcoma

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.

Dipen J. Parekh, MD

Latest:

Landmark Trial Puts Robotic Surgery to the Test in Bladder Cancer

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Dipti Gupta, MD, MPH, Memorial Sloan Kettering Cancer Center

Dirk Arnold, MD, PhD

Dirk Arnold, MD, PhD is Director of the Asklepios Tumorzentrum Hamburg, a network cancer centre serving 7 community hospitals in Hamburg, and also Head of the department of Oncology, Haematology and Palliative Care at AK Altona, Hamburg

Latest:

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Dirk Arnold, MD, PhD, Instituto CUF de Oncologia

Dirk Arnold, MD, PhD, KTB Klinik fur Tumorbiologie GmbH & Co. KG

Dirk Arnold, MD, PhD, Tumor Biology Center

Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center

Dirk Schadendorf, MD

Latest:

Dr. Schadendorf Discusses Sequencing Agents in Melanoma

Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.

Dirk Schadendorf, MD, PhD, West German Cancer Center at University Hospital Essen

Dirk Schadendorf, MD, University Hospital Essen

Latest:

Future Directions in Metastatic Melanoma

Dirk Schadendorf, MD, West German Cancer Center